Arvanna

Arvanna is a biotechnology company dedicated to developing first-in-class small molecule therapeutics for previously undruggable oncology targets. Founded on pioneering research from the University of Michigan, the company specifically focuses on inhibiting transcription factors such as MYC, which are central drivers in many human cancers. Arvanna utilizes a proprietary platform to identify and optimize compounds that disrupt protein-protein interactions and transcriptional complexes. Their lead programs are currently in the pre-clinical stage, aiming to address high unmet needs in solid tumors and hematological malignancies. The company is headquartered in Ann Arbor, Michigan, and leverages deep expertise in chemical biology and translational oncology.